[ET Net News Agency, 23 January 2026] UBS raised the target price for RemeGen (09995) to HKD120 from HKD63.8 and upgraded the rating to "buy" from "neutral".
The research house said it is positive on the recent partnership with AbbVie. (rc)
The research house said it is positive on the recent partnership with AbbVie. (rc)